Video encyclopedia



PEA and FAAH inhibitors


FAAH inhibitors and their complications; value of palmitoylethanolamide

BIA 10-2474 is an experimental fatty acid amide hydrolase inhibitor developed by the Portuguese pharmaceutical company Bial-Portela & Ca. SA. It interacts with the human endocannabinoid system. The drug was in development for the treatment of a range of different medical conditions from anxiety disorder to Parkinson's disease, also for the treatment of chronic pain of multiple sclerosis, cancer, hypertension or the treatment of obesity. A clinical trial with this drug was underway in Rennes, France, in January 2016, in which serious adverse events occurred affecting five participants, including the death of one man. The underlying mechanism that caused the acute neurotoxicity of this molecule remains unknown.
Explore contextually related video stories in a new eye-catching way. Try Combster now!
  • Structure and action 

  • Preclinical studies 

  • Phase I clinical trial 

  • Death and serious adverse events 

  • Reaction and investigations 

  • Outcome for trial participants 

  • Implications for other FAAH inhibitors